Retina Society 2024

I am a healthcare professional

Notice

Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.

Cookies

We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.

I am a healthcare professional in the United States

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

Medical Materials

Agenda

Coming soon

08:59 AM

Duration 5mins PEDRO LEITAO BALLROOM

Port Delivery System With Ranibizumab (PDS) for Continuous Treatment of Diabetic Macular Edema (DME): 2-Year Data From the Phase 3 Pagoda Trial

Regillo C, Awh C, Graff J, Bobbala A, Dakouras A, Howard D, Gune S, Malhotra V, Quezada-Ruiz C, Rabena M

Ophthalmology | Diabetic Macular Edema

03:00 PM

Duration 5mins PEDRO LEITAO BALLROOM

Technical Updates to the Port Delivery System With Ranibizumab for the Treatment of Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Diabetic Retinopathy

Mittra R, Chang M, Pieramici D, Pearce I, Campochiaro P, Holekamp N, Gune S, Quezada Ruiz C, Singh N, Wise G, Ranade S, Horvath J, Regillo

Ophthalmology | Neovascular Age Related Macular Degeneration

06:52 AM

Duration 5mins PEDRO LEITAO BALLROOM

Treat-and-Extend Dosing with Faricimab▼ in the Phase 3 BALATON and COMINO Retinal Vein Occlusion Trials: 72-week Results and Real-world Patient Cases

Suner I, Abreu F, Arrisi P, Kotecha A, Liu Y, Paris L, Retiere A, Willis J

Ophthalmology | Retinal Vein Occlusion

08:29 AM

Duration 4mins PEDRO LEITAO BALLROOM

Real-World Effectiveness of Faricimab▼ in Patients With Neovascular Age-Related Macular Degeneration: 12-Month Outcomes From FARETINA-nAMD and FARWIDE-nAMD Studies

Singh R, Tabano D, Ko S, Borkar D, Leng T, Myrick A, Talks J, Peto T, Dayal P, Chi G

Ophthalmology | Neovascular Age Related Macular Degeneration

07:41 AM

Duration 3mins PEDRO LEITAO BALLROOM

Imaging Biomarkers Supporting the Role of Ang-2 in Dual Inhibition With Faricimab▼ for the Treatment of nAMD and DME

Ali F, Lim J, Singh R, Gibson K, Margaron P, Patel S, Sim D, Yang M

Ophthalmology | Diabetic Macular Edema

07:53 AM

Duration 3mins PEDRO LEITAO BALLROOM

Response of Large Pigment Epithelial Detachments to Faricimab▼ Versus Aflibercept in Patients With nAMD: A Subgroup Analysis From TENAYA and LUCERNE

Ferrone P, Ambresin A, Avery R, Chaikitmongkol V, Eter N, Gomi F, Khanani A, Lai T, Lim J, London N, Harrell E, Margaron P, Patel S, Souverain A, Yang M

Ophthalmology | Neovascular Age Related Macular Degeneration

07:56 AM

Duration 3mins PEDRO LEITAO BALLROOM

Association of Early Fluid Resolution With Short- and Long-Term Extended Durability in the Head-to-Head Phase of the TENAYA/LUCERNE Trials in Patients With Neovascular Age-Related Macular Degeneration Treated With Faricimab▼

Pitcher J, Gallego-Pinazo R, Amador M, Dagincourt N, Stoilov I, Margaron P

Ophthalmology | Neovascular Age Related Macular Degeneration

07:59 AM

Duration 3mins PEDRO LEITAO BALLROOM

Analysis of Extended Interval Treatment Outcomes and Potential Q20W Dosing in nAMD With Faricimab▼ from the TENAYA/LUCERNE Trials

Tan C, Ambresin A, Koh A, Patel P, Singer M, Dagincourt N, Hill L, Kotecha A, Margaron P

Ophthalmology | Neovascular Age Related Macular Degeneration

10:23 AM

Duration 5mins PEDRO LEITAO BALLROOM

Port Delivery System With Ranibizumab for Continuous Treatment in Diabetic Retinopathy: First Readout of 2-Year Data From the Phase 3 Pavilion Trial

Awh C, Khanani A, Chang M, Holmes W, Latkany P, Menezes A, Santhanakrishnan A, Tian K, Wetzel-Smith M

Ophthalmology | Diabetic Retinopathy

10:28 AM

Duration 5mins PEDRO LEITAO BALLROOM

Patient Preference for the Port Delivery System With Ranibizumab (PDS) vs Intravitreal Injections: Results From the Phase 3 Pagoda Trial in Patients With Diabetic Macular Edema (DME)

Marcus D, Chang M, Koh A, Baldonado K, Daly A, Hill L, Poloz Y, Prager A, Menezes A, Tian K

Ophthalmology | Diabetic Macular Edema

10:49 AM

Duration 5mins PEDRO LEITAO BALLROOM

Impact of Early Intraretinal Fluid Reduction (IRF) on One-Year Outcomes in Diabetic Macular Edema (DME)

Sadda, V, Lim J, Wang Y, Hibar D, Maunz A, Lu H, Albrecht T, Gibson K, Willis J, Chang D, Litts K

Ophthalmology | Diabetic Macular Edema

10:54 AM

Duration 5mins PEDRO LEITAO BALLROOM

Real-World Effectiveness of Faricimab▼ in Patients With Diabetic Macular Edema: 12-Month Outcomes From FARETINA-DME and FARWIDE-DME Studies

Borkar D, Tabano D, Ko S, Leng T, Myrick A, Singh R, Talks J, Peto T, Dayal P, Chi G

Ophthalmology | Diabetic Macular Edema

11:19 AM

Duration 5mins PEDRO LEITAO BALLROOM

Faricimab▼ in DME: Results From the RHONE-X Long-Term Extension Trial

Lai T, Schlottmann P, Khanani A, Kotecha A, Idowu O, Harrell E, Abreu F, Tang Y, Willis J

Ophthalmology | Diabetic Macular Edema

07:41 AM

Duration 5mins PEDRO LEITAO BALLROOM

Predictors of Extended Treatment Intervals in Patients With Diabetic Macular Edema (DME) Treated With Faricimab▼ in the Phase 3 YOSEMITE/RHINE Trials

Arevalo F, Ambresin A, Gibson K, Sim D, Hill L

Ophthalmology | Diabetic Macular Edema

07:46 AM

Duration 5mins PEDRO LEITAO BALLROOM

Greater Reduction in Hard Exudates With Faricimab▼ vs Aflibercept in Patients With DME: Biomarker Results From the Phase 3 YOSEMITE/RHINE Trials

Pollreisz A, Dinah C, Goldberg R, Ip M, Rahimy E, Vujosevic S, Amador M, Gibson K, Glittenberg C, Maunz A, O'Leary O, Uschner D

Ophthalmology | Diabetic Macular Edema

07:51 AM

Duration 5mins PEDRO LEITAO BALLROOM

Comparison of the Relative Effectiveness of Faricimab▼ vs Aflibercept 8 mg in Diabetic Macular Edema (DME)

Siedlecki J, Leng T, Holekamp N, Mar F, Leng T, Gibson K, Paulo T, Buehrer C, Tabano D

Ophthalmology | Diabetic Macular Edema

09:47 AM

Duration 5mins PEDRO LEITAO BALLROOM

The Clinical Impact of Continuous Delivery of Ranibizumab With the Port Delivery System (PDS) in Neovascular Age-Related Macular Degeneration (nAMD) in Portal and Archway

Rachitskaya A, Holekamp N, Dauletbekov D, Blotner S, Heinrich D

Ophthalmology | Neovascular Age Related Macular Degeneration

I am a healthcare professional

Notice

Cookies

External site

Retina Society 2024